Facebook
X
LinkedIn
Forward
The Latest Breakthroughs in LG-IR-NMIBC (2025) Webinar
The American Urological Association is proud to offer The Latest Breakthroughs in LG-IR-NMIBC, a dynamic educational activity designed specifically for the urologic care team. This program addresses key educational gaps and barriers in the management of low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)—as identified in the AUA’s Bladder Cancer Global Needs Assessments.
Stay at the forefront of clinical excellence with the most current insights into LG-IR-NMIBC treatment. Whether you're a urologist, advanced practice provider or part of the urologic care team, this activity will provide timely updates on evolving guidelines, novel therapies and best practices for delivering the highest standard of patient care.
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
- UroGen Pharma, Inc.
Target Audience
- Urologists
- APPs
- Residents/Fellows
Learning Objectives
After participating in this CME activity, participants will be able to:
- Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes.
- Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns.
- Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments.
- Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval).
- Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies.
- Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery.
Welcome and Introductions
Pre-test
Segment 1: Updated clinical evidence and treatment protocols
Segment 2: Clinical decision-making related to risk stratification and surveillance strategies
Segment 3: Evidence-based, patient-centered treatment selection options
Segment 4: Interpret the efficacy and safety profiles of new therapies
Segment 5: New medications in the evolving treatment landscape
Segment 6: Impact of treatment options on patient-reported outcomes
Post-test
Wrap-up
| Name | Company Name | Relationship Type | End Date |
| Donahue, Meredith | No relevant financial relationships to disclose | ||
| Filippou, Pauline | No relevant financial relationships to disclose | ||
| Laviana, Aaron A. | No relevant financial relationships to disclose | ||
| Schmidt, Bogdana | Urogen Pharma | Consultant or Advisor | 12/05/2025 |
EDUCATION COUNCIL DISCLOSURE
Education Council DTL 2025_1.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup DTL 2025_1.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
ACCREDITATION: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: The American Urological Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation
Registration for The Latest Breakthroughs in LG-IR-NMIBC (2025) is complimentary, however should you need to cancel your participation for any reason, please let us know at least two weeks before the course by contacting [email protected].
To join the live virtual course:
- Click on the TAKE COURSE button.
- Click “Live Virtual Course” in the Course Progress pane.
- Click the link to register in advance.
- After registering, you will receive a confirmation email containing information about joining the live virtual course.
Attendee Information & Policies
AUA Anti-Harassment Policy
AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress.
Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at [email protected] or Maureen E. Cones, Esq., AUA General Counsel, at [email protected] or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly.
The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).
Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.
Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.
Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.